Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Bites and Stings × blinatumomab × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 17 Burkitt Lymphoma 11 Leukemia, Biphenotypic, Acute 4 Recurrence 3 Neoplasm, Residual 3 Leukemia 2 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Myelodysplastic Syndromes 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Leukemia, Myelomonocytic, Juvenile 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Large Granular Lymphocytic 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Graft vs Host Disease 1 Down Syndrome 1 Blast Crisis 1 Bites and Stings 1

Interventions

enzalutamide 1 durvalumab 1 dostarlimab 1 cemiplimab 1 blinatumomab 1 atezolizumab 1 abiraterone 1 Surgical Instruments 1 Hydroxyurea 1 Etoposide 1 Carboplatin 1 AMG 757 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06063317 2026-03-06

OASIS

Imugene Limited

Phase 1 Terminated

Bites and Stings

Data powered by HemOnc (CC BY 4.0) Colophon ⚡